Paul Whiting is Chief Scientific Officer of The Alzheimer’s Research UK UCL Drug Discovery Institute (ARUK UCL DDI). Established in October 2015, its overarching goal is to develop new therapeutic approaches for neurodegenerative diseases: the dementias, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotropic lateral sclerosis. The unmet medical need is huge, and the rapid advances in our understanding of these diseases mean that this is a very exciting time to take on this challenge. We have initiated a number of projects in key areas: protein toxicity; proteostasis; neuroinflammation; synaptic health and maintenance. Projects broadly have the goal of validating hypotheses around potential drug targets and their role in neurodegenerative disease, and then generating small molecules that appropriately modulate the function of that particular drug target and can be subsequently developed as potential therapeutics. We have a team of neurobiologists, pharmacologists and medicinal chemists to enable us to progress these projects. We work very collaboratively: every project is a collaboration with another PI/ group at UCL, or beyond; a number of our projects also involve collaboration with a pharma company, giving us access to unique resources.
The Lead Academic Scientists for the Institute are UCL Profs Giampietro Schiavo, John Hardy and Bart de Strooper.
The ARUK UCL DDI is interested in hearing your ideas regarding new hypotheses and drug targets for therapies for neurodegenerative diseases, and actively seeks opportunities for collaboration. Please contact email@example.com or visit the ARUK UCL DDI website